Online inquiry

IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12589MR)

This product GTTS-WQ12589MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets F11 gene. The antibody can be applied in Thromboembolic diseases research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000128.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2160
UniProt ID P03951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12589MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5772MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ10821MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA M7824
GTTS-WQ8880MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ12119MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MORAb-003
GTTS-WQ5099MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ6533MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CX-191
GTTS-WQ3782MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ11427MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-8897
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW